Since the Hippo pathway is a signalling cascade and interfering the activity of protein kinases can be achieved by medications, developing medication that impacts the activity of upstream kinases of YAP/TAZ, including MST1/2, LATS1/2, MAP4K4, NDR1/2 may contribute to IBD treatments. The gene discussed is MAP4K4; the disease is inflammatory bowel disease.